Boston Scientific (NYS: BSX) reported earnings on July 26. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Boston Scientific missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank and GAAP earnings per share dropped to a loss.
Gross margins increased, operating margins contracted, net margins dropped.
Boston Scientific tallied revenue of $1.83 billion. The 21 analysts polled by S&P Capital IQ predicted revenue of $1.89 billion on the same basis. GAAP reported sales were 7.4% lower than the prior-year quarter's $1.98 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.11. The 21 earnings estimates compiled by S&P Capital IQ forecast $0.10 per share. GAAP EPS were -$2.39 for Q2 compared to $0.10 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 65.8%, 270 basis points better than the prior-year quarter. Operating margin was 13.2%, 130 basis points worse than the prior-year quarter. Net margin was -186.2%, 19,360 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $1.83 billion. On the bottom line, the average EPS estimate is $0.11.
Next year's average estimate for revenue is $7.45 billion. The average EPS estimate is $0.42.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 752 members out of 936 rating the stock outperform, and 184 members rating it underperform. Among 182 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 159 give Boston Scientific a green thumbs-up, and 23 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Boston Scientific is hold, with an average price target of $6.84.
Add Boston Scientific to My Watchlist.
The article Boston Scientific Goes Negative originally appeared on Fool.com.
Seth Jaysonhad no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.